My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Cipla gains after subsidiary forms a pharma joint venture in Iran
Dec 15,2016

The announcement was made after market hours yesterday, 14 December 2016.

Meanwhile, the S&P BSE Sensex was up 97.89 points or 0.37% at 26,700.73.

On the BSE, 18,438 shares were traded in the counter so far as against average daily volume of 1.42 lakh shares in one quarter. The stock had hit a high of Rs 576.20 and a low of Rs 569 so far during the day. The stock had hit a 52-week high of Rs 660 on 29 December 2015. The stock had hit a 52-week low of Rs 458.25 on 25 May 2016.

The stock had outperformed the market over the past one month till 14 December 2016, gaining 3.41% compared with the Sensexs 0.81% fall. The scrip had also outperformed the market in past one quarter, declining 1.42% as against the Sensexs 6.24% fall.

The large-cap company has equity capital of Rs 160.85 crore. Face value per share is Rs 2.

Cipla announced that Cipla Holding B.V., a wholly owned subsidiary of the company in Netherlands, Cipla Netherlands, has entered into a joint venture agreement with its joint venture partner, Ahran Tejarat Company.

Cipla Netherlands will hold a 75% stake in a joint venture company in Iran while Ahran Tejarat will hold the remaining 25% stake. The expected investment by Cipla Netherlands is estimated to be a maximum of Euro 16.875 million.

The joint venture company proposes to undertake manufacturing and marketing of pharmaceutical products in Iran.

As part of the transaction, Issat Company, an existing company in Iran incorporated on 19 January 1998 and currently owned by Ahran Tejarat, is proposed to be used as the JV company for the purposes of the transaction.

Issat Company has a valid pharmaceutical manufacturing license in Iran and also owns certain fixed asset but has not undertaken any business activity since incorporation and as a result does not currently have any turnover.

Cipla Netherlands will initially acquire a 75% stake in Issat Company from the JV partner for a consideration of Euro 1.35 million payable in cash and the balance amount of upto Euro 15.52 million is expected to be infused by Cipla Netherlands into Issat Company as equity over next one year period.

The acquisition is expected to be completed by March 2017, subject to completion of conditions precedent and applicable regulatory approvals.

Separately, Cipla announced that a meeting of the board of directors of the company is scheduled to be held on 19 December 2016, to consider the proposal of raising funds through issue of equity shares or American depository receipts or global depository receipts or foreign currency convertible bonds or non-convertible debentures- in the form of bonds or otherwise or bonds or any other securities/financial instruments, whether denominated in Indian Rupee and/or foreign currency(ies), either by way of a public issue or by way of a private placement, including through a qualified institutions placement in accordance with the provisions of the applicable law.

The fund raising would be subject to necessary permissions, sanctions and approvals, including shareholders approval and such other statutory approvals as may be required and the provisions of the laws.

On a consolidated basis, Ciplas net profit dropped 34.7% to Rs 354.34 crore on 8.7% rise in net sales to Rs 3671.88 crore in Q2 September 2016 over Q2 September 2015.

Cipla is a global pharmaceutical company.

Powered by Capital Market - Live News

Axis Bank climbs up after board approves allotment of debentures
Dec 15,2016

The announcement was made after market hours yesterday, 14 December 2016.

Meanwhile, the BSE Sensex was down 60.39 points, or 0.23%, to 26,542.45.

On the BSE, 31,213 shares were traded in the counter so far, compared with average daily volume of 7.15 lakh shares in the past one quarter. The stock had hit a high of Rs 469.50 and a low of Rs 456.10 so far during the day.

Axis Bank said that the board of directors approved the allotment of 35,000 unsecured, subordinated, perpetual additional tier 1, Basel III compliant non convertible debentures (Series - 26) of face value of Rs 10 lakh each aggregating Rs 3500 crore on private placement basis.

Axis Banks net profit declined 83.3% to Rs 319.08 crore on 14.1% growth in total income to Rs 13698.77 crore in Q2 September 2016 over Q2 September 2015.

Axis Bank is one of the biggest private sector banks in India.

Powered by Capital Market - Live News

Sunteck Realty corrects on profit booking
Dec 14,2016

Meanwhile, the BSE Sensex was down 82.06 points, or 0.31%, to 26,615.76.

On the BSE, so far 2.25 lakh shares were traded in the counter, compared with average daily volumes of 35,770 shares in the past one quarter. The stock had hit a high of Rs 230.40 and a low of Rs 219 so far during the day.

The stock hit a 52-week high of Rs 300 on 30 October 2016. The stock hit a 52-week low of Rs 173 on 12 February 2016. The stock had outperformed the market over the past 30 days till 13 December 2016, rising 6.18% compared with the 0.45% decline in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 10.53% as against Sensexs 5.90% decline.

The small-cap company has equity capital of Rs 12.59 crore. Face value per share is Rs 2.

Shares of Sunteck Realty rose 18.41% in four trading sessions to settle at Rs 227.65 yesterday, 13 December 2016, from its close of Rs 192.25 on 7 December 2016.

The stock surged 9.55% to Rs 227.65 yesterday, 13 December 2016, after the company reported robust Q2 earnings after market hours on Monday, 12 December 2016. Sunteck Realtys net profit surged 526.40% to Rs 97.28 crore on 582.32% rise in total income from operations to Rs 206.06 crore in Q2 September 2016 over Q2 September 2015.

Sunteck Realty (SRL) is a Mumbai‐based real estate development company, catering to the premium ultra‐luxury and luxury residential segment.

Powered by Capital Market - Live News

Royal Orchid Hotels advances after adding two more hotels
Dec 14,2016

The announcement was made after market hours yesterday, 13 December 2016.

Meanwhile, the BSE Sensex was down 48.55 points, or 0.18%, to 26,649.27.

On the BSE, 9,542 shares were traded in the counter so far as against average daily volume of 16,342 shares in the past one quarter. The stock had hit a high of Rs 77.65 and a low of Rs 74.60 so far during the day. The stock had hit a 52-week high of Rs 115.10 on 11 January 2016. The stock had hit a 52-week low of Rs 56.60 on 17 February 2016.

The stock had outperformed the market over the past 30 days till 13 December 2016, rising 1.52% compared with 0.45% decline in the Sensex. The scrip had also outperformed the market in past one quarter, gaining 19.3% as against Sensexs 5.84% decline.

The small-cap company has equity capital of Rs 27.23 crore. Face value per share is Rs 10.

Royal Orchid Hotels announced the opening of two hotels under its brand Regenta Inn in Vadodara and Kolkata, which are slated to open on 15 December 2016, expanding count to 40 hotels by the end of 2016.

The brand Regenta Hotels is an upscale arm of the Royal Orchid Hotels group. It is categorized into Regenta, Regenta Central, Regenta Resorts and Regenta Inn.

Royal Orchid Hotels net profit rose 33.7% to Rs 2.74 crore on 8.7% decline in net sales to Rs 19.19 crore in Q2 September 2016 over Q2 September 2015.

Royal Orchid Hotels operates business and leisure hotels in popular destinations.

Powered by Capital Market - Live News

Lupin marches ahead after receiving final USFDA approval for generic ointment
Dec 14,2016

The announcement was made during market hours today, 14 December 2016.

Meanwhile, the BSE Sensex was down 26.61 points, or 0.1%, to 26,671.21.

On the BSE, 20,653 shares were traded on the counter so far as against the average daily volumes of 96,866 shares in the past one quarter. The stock had hit a high of Rs 1,509 and a low of Rs 1,482.40 so far during the day. The stock had hit a 52-week high of Rs 1,911.55 on 9 February 2016. The stock had hit a 52-week low of Rs 1,294.05 on 29 March 2016.

The stock had outperformed the market over the past 30 days till 13 December 2016, gaining 2.19% compared with 0.45% decline in the Sensex. The scrip had also outperformed the market in past one quarter, falling 2.67% as against Sensexs 5.84% decline.

The large-cap company has equity capital of Rs 90.27 crore. Face value per share is Rs 2.

Lupin announced that it has received final approval for its Desoximetasone Ointment USP, 0.05% from the United States Food & Drug Administration (USFDA) to market a generic version of Taro Pharms Norths Topicort Ointment, 0.05%. The product filing is from Lupins Pithampur, Indore manufacturing facility.

Lupins Desoximetasone Ointment USP, 0.05% is the AB rated generic equivalent of Taro Pharms Norths Topicort Ointment, 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Topicort Ointment had annual US sales of $12.1 million as per the IMS MAT September 2016 data.

Earlier this month, Lupin had received final approval for its Desoximetasone Ointment USP, 0.25% from US FDA to market a generic version of Taro Pharmaceuticals, Inc.s Topicort Ointment, 0.25% having annual US sales of $14.4 million as per the IMS MAT September 2016 data.

Lupins consolidated net profit jumped 57.8% to Rs 662.19 crore on 31.9% rise in net sales to Rs 4211.18 crore in Q2 September 2016 over Q2 September 2015.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Powered by Capital Market - Live News

Lupin marches ahead after receiving final USFDA approval for generic ointment
Dec 14,2016

The announcement was made during market hours today, 14 December 2016.

Meanwhile, the BSE Sensex was down 26.61 points, or 0.1%, to 26,671.21.

On the BSE, 20,653 shares were traded on the counter so far as against the average daily volumes of 96,866 shares in the past one quarter. The stock had hit a high of Rs 1,509 and a low of Rs 1,482.40 so far during the day. The stock had hit a 52-week high of Rs 1,911.55 on 9 February 2016. The stock had hit a 52-week low of Rs 1,294.05 on 29 March 2016.

The stock had outperformed the market over the past 30 days till 13 December 2016, gaining 2.19% compared with 0.45% decline in the Sensex. The scrip had also outperformed the market in past one quarter, falling 2.67% as against Sensexs 5.84% decline.

The large-cap company has equity capital of Rs 90.27 crore. Face value per share is Rs 2.

Lupin announced that it has received final approval for its Desoximetasone Ointment USP, 0.05% from the United States Food & Drug Administration (USFDA) to market a generic version of Taro Pharms Norths Topicort Ointment, 0.05%. The product filing is from Lupins Pithampur, Indore manufacturing facility.

Lupins Desoximetasone Ointment USP, 0.05% is the AB rated generic equivalent of Taro Pharms Norths Topicort Ointment, 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Topicort Ointment had annual US sales of $12.1 million as per the IMS MAT September 2016 data.

Earlier this month, Lupin had received final approval for its Desoximetasone Ointment USP, 0.25% from US FDA to market a generic version of Taro Pharmaceuticals, Inc.s Topicort Ointment, 0.25% having annual US sales of $14.4 million as per the IMS MAT September 2016 data.

Lupins consolidated net profit jumped 57.8% to Rs 662.19 crore on 31.9% rise in net sales to Rs 4211.18 crore in Q2 September 2016 over Q2 September 2015.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Powered by Capital Market - Live News

Kaveri Seeds Company leads losers in A group
Dec 14,2016

Kaveri Seeds Company slumped 6.09% to Rs 403 at 13:55 IST. The stock topped the losers in the BSEs A group. On the BSE, 3.58 lakh shares were traded on the counter so far as against the average daily volumes of 25,000 shares in the past two weeks.

Indiabulls Housing Finance slipped 3.66% at Rs 645.05. The stock was the second biggest loser in A group. On the BSE, 2.46 lakh shares were traded on the counter so far as against the average daily volumes of 49,000 shares in the past two weeks.

Coal India fell 3.57% to Rs 294.85 after consolidated net profit fell 77.37% to Rs 600.44 crore on 6.77% decline in total income to Rs 17625.09 crore in Q2 September 2016 over Q2 September 2015. The result was announced after market hours yesterday, 13 December 2016. The stock was the third biggest loser in A group. On the BSE, 4.63 lakh shares were traded on the counter so far as against the average daily volumes of 1.77 lakh shares in the past two weeks.

Amtek Auto declined 3.32% to Rs 36.40 after the company posted net loss of Rs 755.18 crore in Q2 September 2016 compared with net loss of Rs 158.62 crore in Q2 September 2015. The result was announced after market hours yesterday, 13 December 2016. The stock was the fourth biggest loser in A group. On the BSE, 2.46 lakh shares were traded on the counter so far as against the average daily volumes of 4.76 lakh shares in the past two weeks.

GMDC dropped 3.27% at Rs 97.75. The stock was the fifth biggest loser in A group. On the BSE, 1.08 lakh shares were traded on the counter so far as against the average daily volumes of 1.25 lakh shares in the past two weeks.

Powered by Capital Market - Live News

Kaveri Seeds Company leads losers in A group
Dec 14,2016

Kaveri Seeds Company slumped 6.09% to Rs 403 at 13:55 IST. The stock topped the losers in the BSEs A group. On the BSE, 3.58 lakh shares were traded on the counter so far as against the average daily volumes of 25,000 shares in the past two weeks.

Indiabulls Housing Finance slipped 3.66% at Rs 645.05. The stock was the second biggest loser in A group. On the BSE, 2.46 lakh shares were traded on the counter so far as against the average daily volumes of 49,000 shares in the past two weeks.

Coal India fell 3.57% to Rs 294.85 after consolidated net profit fell 77.37% to Rs 600.44 crore on 6.77% decline in total income to Rs 17625.09 crore in Q2 September 2016 over Q2 September 2015. The result was announced after market hours yesterday, 13 December 2016. The stock was the third biggest loser in A group. On the BSE, 4.63 lakh shares were traded on the counter so far as against the average daily volumes of 1.77 lakh shares in the past two weeks.

Amtek Auto declined 3.32% to Rs 36.40 after the company posted net loss of Rs 755.18 crore in Q2 September 2016 compared with net loss of Rs 158.62 crore in Q2 September 2015. The result was announced after market hours yesterday, 13 December 2016. The stock was the fourth biggest loser in A group. On the BSE, 2.46 lakh shares were traded on the counter so far as against the average daily volumes of 4.76 lakh shares in the past two weeks.

GMDC dropped 3.27% at Rs 97.75. The stock was the fifth biggest loser in A group. On the BSE, 1.08 lakh shares were traded on the counter so far as against the average daily volumes of 1.25 lakh shares in the past two weeks.

Powered by Capital Market - Live News

Bombay Rayon Fashions edges lower after reverse turnaround in Q2
Dec 14,2016

The result was announced after market hours yesterday, 13 December 2016.

Meanwhile, the BSE Sensex was down 37.51 points, or 0.14%, to 26,660.31.

On the BSE, 653 shares were traded in the counter so far, compared with an average volume of 5,086 shares in the past one quarter. The stock had hit a high of Rs 142 and a low of Rs 139.70 so far during the day. The stock had hit a 52-week low of Rs 129 on 26 April 2016. The stock had hit a 52-week high of Rs 198 on 1 August 2016.

The stock had outperformed the market over the past 30 days till 13 December 2016, rising 1.03% compared with 0.45% decline in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 10.61% as against Sensexs 5.84% decline.

The small-cap company has an equity capital of Rs 183 crore. Face value per share is Rs 10.

Bombay Rayon Fashions net total income from operations fell 1.18% to Rs 981.63 crore in Q2 September 2016 over Q2 September 2015.

Bombay Rayon Fashions is engaged in manufacturing textiles consisting of fabrics and garments.

Powered by Capital Market - Live News

Sandesh drops after reporting disappointing Q2 results
Dec 14,2016

The result was announced after market hours yesterday, 13 December 2016.

Meanwhile, the BSE Sensex was down 13.35 points, or 0.05%, to 26,684.47.

More than usual volumes were witnessed on the counter. On the BSE, 2,578 shares were traded in the counter so far, compared with an average volume of 1,292 shares in the past one quarter. The stock had hit a high of Rs 950 and a low of Rs 899 so far during the day. The stock had hit a 52-week low of Rs 655 on 29 February 2016. The stock had hit a record high of Rs 1,080 on 19 August 2015.

The stock had outperformed the market over the past 30 days till 13 December 2016, rising 7.06% compared with 0.45% decline in the Sensex. The scrip had also outperformed the market in past one quarter, gaining 11.83% as against Sensexs 5.84% decline.

The small-cap company has an equity capital of Rs 7.57 crore. Face value per share is Rs 10.

Sandesh is engaged in the editing, printing and publishing newspapers and periodicals.

Powered by Capital Market - Live News

Omkar Speciality Chemicals gains after winning patent
Dec 14,2016

The announcement was made at the fag end of the trading session yesterday, 13 December 2016.

Meanwhile, the BSE Sensex was down 38.28 points, or 0.14%, to 26,659.54.

On the BSE, so far 1.16 lakh shares were traded in the counter, compared with average daily volumes of 49,749 shares in the past one quarter. The stock had hit a high of Rs 173.20 and a low of Rs 167.20 so far during the day.

The stock hit a record high of Rs 249.10 on 13 January 2016. The stock hit a 52-week low of Rs 130.05 on 9 November 2016. The stock had outperformed the market over the past 30 days till 13 December 2016, rising 10.05% compared with the 0.45% decline in the Sensex. The scrip had also outperformed the market in past one quarter, falling 0.67% as against Sensexs 5.90% decline.

The small-cap company has equity capital of Rs 20.58 crore. Face value per share is Rs 10.

Omkar Speciality Chemicals said it has obtained a patent related to the process for preparation of higher derivatives of β -KETOESTER granted by the Government of India. With this, the total number of patents till date granted to the company stands at 4.

β -KETOESTERS are one of the basic building blocks from which advance molecules can be synthesized. It is used in various therapies such as cardiovascular diseases, treatment of dyslipidemia (cholesterol), various application in anti-microbial/anti-fungal activity and in synthesis of certain photographic chemicals.

Meanwhile, the company said it has applied for more process patents n++ some of which are expected in over the next 12-18 months. The product range covered under the above patents are iodo-alkalibenzoic acids, hydroxy diiodobenzoic acids, benzeneseleninic anhydride, alkali metal lodides, terminal dihaloalkanes, benzisothiazols, halquinol product, coumarin product, bromo amino derivatives of phenylene and iodine derivatives of alkanes.

On a consolidated basis, net profit of Omkar Speciality Chemicals rose 28.30% to Rs 11.56 crore on 27.80% rise in net sales to Rs 129.40 crore in Q2 September 2016 over Q2 September 2015.

Omkar Speciality Chemicals is amongst the leading manufacturers of specialty chemicals and intermediates for chemical and allied industries.

Powered by Capital Market - Live News

South Indian Bank gains after board plans to consider rights issue
Dec 14,2016

The announcement was made during market hours today, 14 December 2016.

Meanwhile, the BSE Sensex was down 44.52 points, or 0.17%, to 26,653.30.

On the BSE, 6.29 lakh shares were traded in the counter so far as against average daily volume of 7.39 lakh shares in the past one quarter. The stock hit high of Rs 22.50 and low of Rs 21.80 so far during the day. The stock had hit a 52-week high of Rs 25.55 on 7 October 2016. The stock had hit a 52-week low of Rs 16.40 on 29 February 2016.

The stock had underperformed the market over the past one month till 13 December 2016, falling 6% compared with 0.45% decline in the Sensex. The scrip had, however, outperformed the market in past one quarter, falling 4.57% as against Sensexs 5.84% decline.

The mid-cap bank has equity capital of Rs 135.17 crore. Face value per share is Re 1.

South Indian Banks net profit rose 18.4% to Rs 110.52 crore on 4.6% growth in total income to Rs 1596.08 crore in Q2 September 2016 over Q2 September 2015.

South Indian Bank is a private sector bank in India.

Powered by Capital Market - Live News

Bajaj Electricals rises after entering into strategic alliance with UK-based firm
Dec 14,2016

The announcement was made after market hours yesterday, 13 December 2016.

Meanwhile, the BSE Sensex was down 45.30 points, or 0.17%, to 26,652.52.

On the BSE, so far 8,998 shares were traded in the counter, compared with average daily volumes of 33,061 shares in the past one quarter. The stock had hit a high of Rs 225 and a low of Rs 220 so far during the day.

The stock hit a 52-week high of Rs 280 on 10 August 2016. The stock hit a 52-week low of Rs 155.35 on 29 February 2016. The stock had underperformed the market over the past 30 days till 13 December 2016, sliding 2.16% compared with the 0.45% decline in the Sensex. The scrip had also underperformed the market in past one quarter, falling 18.79% as against Sensexs 5.90% decline.

The small-cap company has equity capital of Rs 20.24 crore. Face value per share is Rs 2.

Bajaj Electricals has entered into a strategic alliance with UK-based firm Gooee to take the next step in its journey towards digitization and in creating innovative lighting products and solutions on IoT (Internet of Things) platform. Under this arrangement, Gooee will be the first full stack operating platform providing Bajaj Electricals a service driven framework to deliver IoT applications to their discerning customers. IoT refers to the connection of devices other than computers and smartphones to the internet.

Bajaj Electricals net profit dropped 10.8% to Rs 16.66 crore on 10.4% fall in net sales to Rs 991.56 crore in Q2 September 2016 over Q2 September 2015.

Bajaj Electricals has a diversified business viz - consumer products (appliances, fans, lighting), exports, luminaires and EPC (illumination, transmission towers and power distribution).

Powered by Capital Market - Live News

NTPC nudges higher after announcing fund raising plans
Dec 14,2016

The announcement was made after market hours yesterday, 13 December 2016.

Meanwhile, the BSE Sensex was down 63.99 points, or 0.24%, to 26,633.83.

On the BSE, 15,308 shares were traded in the counter so far, compared with average daily volume of 3.02 lakh shares in the past one quarter. The stock had hit a high of Rs 166.40 and a low of Rs 164.45 so far during the day. The stock had hit a 52-week high of Rs 169.95 on 19 August 2016. The stock had hit a 52-week low of Rs 116.80 on 25 February 2016.

The stock had outperformed the market over the past 30 days till 13 December 2016, rising 8.45% compared with 0.45% decline in the Sensex. The scrip had also outperformed the market in past one quarter, gaining 7.71% as against Sensexs 5.84% decline.

The large-cap company has equity capital of Rs 8245.46 crore. Face value per share is Rs 10.

NTPC announced that it has decided to raise Rs 3925 crore through private placement of secured non-convertible debentures at a coupon of 7.37% per annum with a door to door maturity of 15 years today, 14 December 2016.

The proceeds will be utilized to finance capital expenditure/refinancing the debt requirement in on-going projects and other general corporate requirements.

NTPCs net profit declined 17.9% to Rs 2495.97 crore on 8.4% rise in net sales to Rs 19241.47 crore in Q2 September 2016 over Q2 September 2015.

NTPC, Indias largest power company, has presence in the entire value chain of power generation business. The government of India holds 69.75% stake in the company as per the shareholding pattern as at 30 September 2016.

Powered by Capital Market - Live News

Wockhardt gains as Daman plant gets GMP certificate from UK MHRA
Dec 14,2016

The announcement was made after market hours yesterday, 13 December 2016.

Meanwhile, the BSE Sensex was down 54.22 points, or 0.20%, to 26,643.60.

On the BSE, so far 1.18 lakh shares were traded in the counter, compared with average daily volumes of 2.85 lakh shares in the past one quarter. The stock had hit a high of Rs 719 and a low of Rs 705.10 so far during the day.

The stock hit a 52-week high of Rs 1,654 on 18 December 2015. The stock hit a 52-week low of Rs 659 on 23 November 2016. The stock had underperformed the market over the past 30 days till 13 December 2016, falling 11.91% compared with the 0.45% decline in the Sensex. The scrip had also underperformed the market in past one quarter, falling 17.05% as against Sensexs 5.90% decline.

The mid-cap company has equity capital of Rs 55.27 crore. Face value per share is Rs 5.

Wockhardt announced that UK MHRA (The Medicines and Healthcare products Regulatory Agency) has confirmed that the companys manufacturing unit at Kadaiya, Daman complies with the principles and guidelines of Good Manufacturing Practices. In view of this, the approval status of the unit continues.

Wockhardts consolidated net profit fell 81.59% to Rs 17.02 crore on 10.05% decline in total income to Rs 1084.59 crore in Q2 September 2016 over Q2 September 2015.

Wockhardt is a research based and technology intensive global pharmaceutical and biotechnology company.

Powered by Capital Market - Live News